Your browser doesn't support javascript.
loading
Targeting amyloid ß in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.
Holdridge, Karen C; Yaari, Roy; Hoban, Deirdre B; Andersen, Scott; Sims, John R.
Affiliation
  • Holdridge KC; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Yaari R; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Hoban DB; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Andersen S; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Sims JR; Eli Lilly and Company, Indianapolis, Indiana, USA.
Alzheimers Dement ; 19(10): 4619-4628, 2023 10.
Article in En | MEDLINE | ID: mdl-36946603
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Alzheimers Dement Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Alzheimers Dement Year: 2023 Document type: Article Affiliation country: Country of publication: